CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Tandem t:slim X2 with Control-IQ Technologydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03368937
NCT03368937N/ACompleted
CompareCT.gov

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas - A Pilot Test of t:Slim X2 With Control-IQ Technology

University of Virginia·interventional·Posted Dec 11, 2017·Updated May 25, 2022

In Brief

A clinical study evaluating Tandem t:slim X2 with Control-IQ Technology for Type1 Diabetes Mellitus. Completed, enrolled 5 participants across 1 site.

Detailed Summary

A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType1 Diabetes Mellitus
CountriesUnited States
CollaboratorsTandem Diabetes Care, Inc., DexCom, Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 11, 2017
Enrollment StartDec 8, 2017
Primary CompletionDec 11, 2017
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 8.6 years ago

Interventions

Tandem t:slim X2 with Control-IQ Technologydevice

Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.